Teva licenses glatiramer acetate to Takeda in Japan

[MSUK]

Teva Pharmaceutical has licensed rights to commercialize glatiramer acetate to Takeda Pharmaceutical in Japan as part of their agreement signed earlier in 2013.<br><br>

Currently both the firms are working on additional agreements for implementation of the license..... Read More - http://www.ms-uk.org/copaxone

[NHE]

Under the deal, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application (NDA) for registration of glatiramer acetate in Japan.

This sounds like a way for Teva to potentially extend their patent vicariously through Takeda and then collect license fees for the duration of Takeda's production of Copaxone.